U-Blot® Research Grade Tamtuvetmab
Ucallm.jpg
$9,999.00
Product details
Background：Tamtuvetmab (AT-005) is a caninised blontuvetmab against CD52. Tamtuvetmab increases progression-free survival (PFS), exhibits in vivo efficacy in dogs with naïve T-cell lymphoma (LSA). Tamtuvetmab has been approved by veterinary.
• CD52 antigen–a review., PMID:11257744
• Anti-CD52 Therapy for Multiple Sclerosis: An Update in the COVID Era., PMID:34268256
• CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma., PMID:37975535
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)., PMID:29447988
• Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors., PMID:38242120
• The immunological function of CD52 and its targeting in organ transplantation., PMID:28283679
• CD52 (CAMPATH1)., PMID:11860230
• Preoperative CD52 Level Predicts Graft Survival following Kidney Transplantation., PMID:39281063
• CD52 and OXPHOS-potential targets in ibrutinib-treated mantle cell lymphoma., PMID:36587029
• CD52-targeted depletion by Alemtuzumab ameliorates allergic airway hyperreactivity and lung inflammation., PMID:33731828
Specifications
| Target | CD52 |
| Reactivity | Dog |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| MW(Calculated) | |
| MW(Observed) | |
| Host Species | Caninized |
| Isotype | IgG2-kappa-lambda |
| Conjugate/Modification | |
| Modification | |
| Recommended Dilution Ratio | |
| Composition | 0.01M PBS, pH 7.4. |
| Purification Process | Protein A/G purified from cell culture supernatant. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Storage Condition | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Concentration | |
| Clonality | Monoclonal |
| Clone Number | |
| Immunogen | Mammalian Cells |
| Gene Name | |
| Protein Name | |
| Alias | CD52 |
| Species | |
| Gene ID-1 | Q28896 |
| Uniprot | |
| Species.1 | |
| Gene ID | |
| Uniprot.1 | |
| Species.2 | |
| Gene ID.1 | |
| Uniprot.2 | |
| Organism-4 | |
| Gene ID-4 | |
| SwissProt-4 | |
| Description | Background：Tamtuvetmab (AT-005) is a caninised blontuvetmab against CD52. Tamtuvetmab increases progression-free survival (PFS), exhibits in vivo efficacy in dogs with naïve T-cell lymphoma (LSA). Tamtuvetmab has been approved by veterinary.<br>• CD52 antigen--a review., PMID:11257744<br />• Anti-CD52 Therapy for Multiple Sclerosis: An Update in the COVID Era., PMID:34268256<br />• CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma., PMID:37975535<br />• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)., PMID:29447988<br />• Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors., PMID:38242120<br />• The immunological function of CD52 and its targeting in organ transplantation., PMID:28283679<br />• CD52 (CAMPATH1)., PMID:11860230<br />• Preoperative CD52 Level Predicts Graft Survival following Kidney Transplantation., PMID:39281063<br />• CD52 and OXPHOS-potential targets in ibrutinib-treated mantle cell lymphoma., PMID:36587029<br />• CD52-targeted depletion by Alemtuzumab ameliorates allergic airway hyperreactivity and lung inflammation., PMID:33731828<br /> |
| Cellular Localization | |
| Tissue Expression | |
| Signaling_pathway | |
| Research Areas | |
| Function |
Please login to post questions
Related products
